ProShare Advisors’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,151
| Closed | -$9.91K | – | 2145 |
|
|
2025
Q1 | $9.91K | Sell |
1,151
-361
| -24% | -$5.57K | ﹤0.01% | 2068 |
|
|
2024
Q4 | $54.1K | Buy |
1,512
+655
| +76% | +$33.9K | ﹤0.01% | 2168 |
|
|
2024
Q3 | $40.5K | Buy |
857
+263
| +44% | +$11.6K | ﹤0.01% | 2000 |
|
|
2024
Q2 | $29.8K | Sell |
594
-203
| -25% | -$14.7K | ﹤0.01% | 1786 |
|
|
2024
Q1 | $89.2K | Buy |
797
+63
| +9% | +$6.26K | ﹤0.01% | 1839 |
|
|
2023
Q4 | $42.6K | Sell |
734
-128
| -15% | -$5.15K | ﹤0.01% | 1878 |
|
|
2023
Q3 | $27.4K | Buy |
862
+44
| +5% | +$2.09K | ﹤0.01% | 1766 |
|
|
2023
Q2 | $67.3K | Buy |
818
+83
| +11% | +$12.1K | ﹤0.01% | 1744 |
|
|
2023
Q1 | $75.5K | Sell |
735
-71
| -9% | -$9.96K | ﹤0.01% | 1631 |
|
|
2022
Q4 | $118K | Buy |
806
+82
| +11% | +$13.9K | ﹤0.01% | 1618 |
|
|
2022
Q3 | $122K | Buy |
724
+28
| +4% | +$4.55K | ﹤0.01% | 1514 |
|
|
2022
Q2 | $80K | Sell |
696
-186
| -21% | -$17.5K | ﹤0.01% | 1645 |
|
|
2022
Q1 | $88K | Sell |
882
-149
| -14% | -$17.4K | ﹤0.01% | 2056 |
|
|
2021
Q4 | $161K | Buy |
1,031
+51
| +5% | +$9.92K | ﹤0.01% | 2107 |
|
|
2021
Q3 | $231K | Sell |
980
-235
| -19% | -$68.7K | ﹤0.01% | 1714 |
|
|
2021
Q2 | $412K | Buy |
1,215
+264
| +28% | +$99.9K | ﹤0.01% | 1676 |
|
|
2021
Q1 | $385K | Buy |
951
+56
| +6% | +$27.2K | ﹤0.01% | 1633 |
|
|
2020
Q4 | $595K | Buy |
+895
| New | +$498K | ﹤0.01% | 1153 |
|
|
2018
Q4 | – | Sell |
-439
| Closed | -$110K | – | 1654 |
|
|
2018
Q3 | $110K | Sell |
439
-12
| -3% | -$4.02K | ﹤0.01% | 1671 |
|
|
2018
Q2 | $201K | Sell |
451
-27
| -6% | -$11.9K | ﹤0.01% | 1606 |
|
|
2018
Q1 | $188K | Sell |
478
-42
| -8% | -$16.6K | ﹤0.01% | 1563 |
|
|
2017
Q4 | $214K | Buy |
+520
| New | +$227K | ﹤0.01% | 1605 |
|
Other funds holding MRSN
NI
BCLSI
SSA
RSCM
SCM
